98634-03-8

Upstream product

• 76-41-5 oxymorphone 
• 1257541-93-7 C₂₄H₂₈N₂O₃ 
• 73986-27-3 C₂₄H₂₆N₂O₃ 
• 357-07-3 oxymorphone hydrochloride 

Downstream Products

• 1443990-81-5 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(1-(19-(((4αS,7S,7αR,12βS)-4α,9-dihydroxy-3-methyl-2,3,4,4α,5,6,7,7α-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-5,15,19-trioxo-3,17-dioxa-6,14-diazanonadecan-1-oyl)piperidin-4-yl)-4-methyl-1H-pyrazole-3-carboxamide 
• 1443990-80-4 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(1-(18-(((4αS,7-S,7αR,12βS)-4α,9-dihydroxy-3-methyl-2,3,4,4α,5,6,7,7α-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-5,14,18-trioxo-3,16-dioxa-6,13-diazaoctadecan-1-oyl)piperidin-4-yl)-4-methyl-1H-pyrazole-3-carboxamide 
• 1443990-79-1 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(1-(14-(((4αS,7S,7αR,12βS)-4α,9-dihydroxy-3-methyl-2,3,4,4α,5,6,7,7α-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-5,10,14-trioxo-3,12-dioxa-6,9-diazatetradecan-1-oyl)piperidin-4-yl)-4-methyl-1H-pyrazole-3-carboxamide 
• 1443990-78-0 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(1-(2-(2-(((4αS,7S,7αR,12βS)-4α,9-dihydroxy-3-methyl-2,3,4,4α,5,6,7,7α-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-2-oxoethoxy)acetyl)piperidin-4-yl)-4-methyl-1H-pyrazole-3-carboxamide 
• 1443990-77-9 4-(5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamido)-N-((4αS,7S,7αR,12βS)-4α,9-dihydroxy-3-methyl-2,3,4,4α,5,6,7,7α-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)piperidine-1-carboxamide 

Relevant academic research and scientific papers

Tuned-affinity bivalent ligands for the characterization of opioid receptor heteromers

Opioid receptors, including the μ- and δ-opioid receptors (MOR and DOR), are important targets for the treatment of pain. Although there is mounting evidence that these receptors form heteromers, the functional role of the MOR/DOR heteromer remains unresolved. We have designed and synthesized bivalent ligands as tools to elucidate the functional role of the MOR/DOR heteromer. Our ligands (L2 and L4) are comprised of a compound with low affinity at the DOR tethered to a compound with high affinity at the MOR, with the goal of producing ligands with "tuned affinity" at MOR/DOR heteromers as compared to DOR homomers. Here, we show that both L2 and L4 demonstrate enhanced affinity at MOR/DOR heteromers as compared to DOR homomers, thereby providing unique pharmacological tools to dissect the role of the MOR/DOR heteromer in pain.

Generation of novel radiolabeled opiates through site-selective iodination

Tritiated opioid radioligands have proven valuable in exploring opioid binding sites. However, tritium has many limitations. Its low specific activity and limited counting efficiency makes it difficult to examine low abundant, high affinity sites and its